In this use case, we compare two Pneumococcal Conjugate Vaccine (PCV) products that were considered for introduction into Papua New Guinea. Comparing different vaccine formulations and profiles is likely an increasing concern for countries that are graduating from Gavi, the vaccine alliance. We additionally review how the tool supports the updating of evidence over time to re-assess prioritization and to explore putative scenarios to reflect future constraints (e.g. costs or storage space requirements).
An interactive, online tool to support deliberations and decision-making using evidence-to-recommendation frameworks.
Considering New Vaccines for Introduction in Uganda